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Abstract
Endogenous nucleic acids and their receptors may be involved in the initiation of
systemic autoimmune diseases including rheumatoid arthritis (RA). As the role of the
DNA sensing Toll-like receptor (TLR) 9 in RA is unclear, we aimed to investigate its
involvement in the pathogenesis of autoimmune arthritis using three different
experimental models of RA. The data obtained revealed involvement of TLR9 in the
T cell-dependent phase of inflammatory arthritis. In rats with pristane-induced
arthritis (PIA), TLR9 inhibition before disease onset reduced arthritis significantly
and almost completely abolished bone erosion. Accordingly, serum levels of IL-6,
a-1-acid-glycoprotein and rheumatoid factor were reduced. Moreover, in TLR9/
mice, streptococcal cell wall (SCW)-induced arthritis was reduced in the T cell-
dependent phase, whereas T cell-independent serum-transfer arthritis was not
affected. Remarkably, while TLR7 expression did not change during in vitro osteo-
clastogenesis, TLR9 expression was higher in precursor cells than in mature osteo-
clasts and partial inhibition of osteoclastogenesis was achieved only by the TLR9
antagonist. These results demonstrate a pivotal role for TLR9 in the T cell-depen-
dent phases of inflammatory arthritis and additionally suggest some role during
osteoclastogenesis. Hence, endogenous DNA seems to be crucially involved in the
pathophysiology of inflammatory autoimmune arthritis.
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1 | INTRODUCTION
Rheumatoid arthritis (RA) is the most common and most severe
inflammatory joint disease. Apart from cartilage degradation, the pre-
dominant clinical feature of RA is bone erosion leading to irreversible
destruction of the joints. The onset of RA is characterized by hyper-
plasia of the synovial lining and infiltration of immune cells such as
neutrophils, T cells, B cells, dendritic cells (DC) or macrophages in
the synovia of the joint.1 In the past years, research has been partic-
ularly focused on autoantibodies and to a lesser extent also on
autoreactive T cells. In the course of these investigations, the impor-
tant role of the innate immune system in eliciting the autoimmune
responses involved in RA has become increasingly evident. A family
of pattern recognition receptors, the Toll-like receptors (TLRs), is
known to bridge the gap between innate and adaptive immunity.
TLRs are highly expressed by antigen-presenting cells (APCs) and
recognize distinct ligands, predominantly components of bacteria,
viruses or fungi, which are referred to as microbe-associated molecu-
lar patterns (MAMPs). Endogenous TLR ligands, which are expressed
or released under stress, are called danger-associated molecular pat-
terns (DAMPs), such as heat shock proteins, some nuclear proteins
and nucleic acids.2-5 To date, 13 TLRs are known in mammals, of
which TLR1 to 11 are conserved between humans and mice. Cell
surface-expressed TLRs are the TLRs 1, 2, 4, 5, 6 and 10, which are
activated by, for example lipopolysaccharides (LPS), flagellins or (bac-
terial) lipoproteins. TLRs 3, 7, 8 and 9 are activated by nucleic acids
and are located inside the cell at the surface of endosomes. TLR
activation induces downstream signaling via mitogen-activated pro-
tein kinases (MAPK) or transcription factors such as nuclear factor of
jB (NFjB) or interferon regulatory factor (IRF), resulting in the
expression of inflammatory cytokines and type I interferon.6 Besides
their central function in modulating immune responses, there is evi-
dence that TLR activation is involved in the processes causing the
loss of tolerance in RA. A role for TLRs in the pathogenesis of RA
has been suggested because these receptors, especially TLR2, 3, 4
and 7, are highly expressed in the synovial tissue of RA patients.7,8
Intra-articular injection of streptococcal cell wall (SCW) lysates con-
taining components of Streptococcus pyogenes that activate TLR2
results in acute T cell-independent joint inflammation9 while
repeated intra-articular exposure to SCW fragments results in TLR4
activation and the development of a chronic destructive arthritis
depending on T cells.10,11 Furthermore, endogenous RNA released
from necrotic cells in the synovial fluid of RA patients has been
shown to activate synovial fibroblasts through TLR3.4 In addition,
involvement of TLR3 and double-stranded (ds) RNA in pristane-
induced arthritis (PIA) has been suggested.12 However, the involve-
ment of TLRs activated by single-stranded (ss) nucleic acids in the
inflammatory processes of RA is not fully understood. It was recently
shown that TLR7 expression is elevated in synovial fluid monocytes
of RA patients and correlates with increased tumour necrosis factor
(TNF)-a levels.13 In addition, reduction of collagen induced arthritis
(CIA) in TLR7/ mice points towards the involvement of the RNA-
binding TLR7 in disease maintenance.14 Other studies suggest a role
for TLR9, which senses unmethylated ssCpG DNA.15 It has been
demonstrated that unmethylated CpG motifs from bacterial DNA
can induce arthritis by activating macrophages and their cytokine
production indicating a pathogenic role for bacterial DNA in septic
arthritis.16 Consequently, inhibition of TLR9 by a suppressive ODN
in CpG-induced arthritis was shown to improve the clinical out-
come.17 In contrast, activation of TLR9 in mice with K/BxN serum
transfer arthritis led to a disease reduction.18 Furthermore, involve-
ment of nucleic acid recognizing TLRs in the pathogenesis of autoim-
mune arthritis has been reported in PIA. In this model, arthritis could
be transferred into na€ıve recipients with T cells that had been re-
activated in vitro by the nucleic acid binding protein hnRNP-A2/B1
or ligands (nucleic acids) of TLR3, TLR7 or TLR9.19 Interestingly, dis-
ease transfer was inhibited by chloroquine or pre-treatment of cells
with nucleases.
To dissect the role of TLR9 in the pathogenesis of RA, we
induced arthritis in TLR9/ mice and blocked TLR9 activation in
PIA by applying suppressive ODNs which have previously been
shown to block TLR9 on murine and human cells in vitro.20,21 The
data obtained demonstrate involvement of TLR9 in the T cell-depen-
dent phases of erosive arthritis, suggesting a pathogenic role of
endogenous DNA and TLR9 in the initiation of arthritogenic autoim-
mune responses.
2 | MATERIALS AND METHODS
2.1 | Toll-like receptor antagonists and agonists
Antagonists for TLR7 (IRS 661), TLR9 (IRS 869), the TLR9 agonist
(1018 ISS) and a control ODN were purchased from Eurofins Geno-
mics (Eurofins Genomics, Ebersberg, Germany). The sequences were
previously published.20,21 Resiquimod (R-848) served as TLR7 ago-
nist (Sigma-Aldrich, St. Louis, USA). For in vitro analysis by flow
cytometry, IRS 869 and the control ODN had a fluorescein modifica-
tion at the 50-end (Eurofins Genomics).
2.2 | Animals
DA.1F rats were bred under conventional conditions at the Institute
for Biomedical Research, Medical University of Vienna, Austria.
C57BL/6 mice were obtained from Jackson Laboratory. In some
experiments, TLR9/ mice (on a C57BL/6 background) and their
respective littermate control mice (TLR9+/+) were used.15 All experi-
ments were carried out in accordance to EU Directive 2010/63/EU
for animal experiments and were approved by the respective local
ethics committees.
2.3 | Pristane-induced arthritis (PIA)
Arthritis was induced in DA.1F rats by subcutaneous (s.c.) injection
of 100 lL pristane (Sigma-Aldrich) at the tail base. Antagonist
(250 lg), control ODN (250 lg) or vehicle was injected s.c. 2 times
weekly, and animals were treated twice before disease induction.
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Inhibitors were diluted in saline to a final volume of 100 lL. Phos-
phate-buffered saline (PBS) served as vehicle control. Rats were
evaluated for arthritis symptoms every other day starting at day 10
after disease induction using a semi-quantitative scoring system.22
Changes in body weight served as an additional measure of disease
severity.22
2.4 | K/BxN serum-transfer arthritis
C57BL/6 mice were injected with 150 lL K/BxN serum intraperi-
toneally (i.p.) on day 1 and on day 3. Clinical scoring was started
after the first serum application using a semi-quantitative scoring
system. Arthritic limbs were scored from 0 to 3 with a maximum
score of 3 per limb and 12 per animal. Grip strength was evaluated
as an additional parameter of arthritis. The animals were sacrificed
on day 10 after serum application.
2.5 | Induction of chronic SCW arthritis
Cell wall fragments from Streptococcus pyogenes T12 were prepared
as described.23 Unilateral chronic arthritis was induced by 4 weekly
intra-articular injections of 25 lg SCW in 6 lL PBS into the right
knee joint at days 0, 7, 14 and 21. The left joint was injected with
saline as control.
2.6 | Quantification of joint swelling in SCW
arthritis
Longitudinal joint swelling at different phases of SCW arthritis
was measured by accumulation of 99mTechnetium (99mTc) in the
inflamed joint on days 1 and 2 (acute phase), days 8, 15 and 22
(reactivation days after each intra-articular injection), and days 23
and 28 as the chronic T cell-dependent phase.11 Swelling was cal-
culated as ratio of gamma counts in the right (inflamed) over the
left (internal control) knee joint. Values higher that 1.1 were con-
sidered inflammation.
2.7 | Histological evaluation of joint inflammation
and local bone destruction
Hind paws were prepared, fixed in formalin for 24 hours and bones
decalcified. Serial paraffin sections were stained with haematoxylin/
eosin (H&E), toluidine blue (TB) or were stained for tartrate-resistant
acid phosphatase (TRAP) expression using leucocyte acid phos-
phatase kit (Sigma-Aldrich). Histomorphometrical analysis was
accomplished using the Osteomeasure software (Osteomeasure 7,
Osteometrics, Georgia, USA).
2.8 | In vitro osteoclast formation assay
Murine bone marrow cells were obtained from femora and tibiae by
cutting the end of the bones and flushing them with a-MEM (Gibco,
Thermo Fisher Scientific, Waltham, USA). The cells were cultured for
3 days in a-MEM supplemented with 10% FCS, 1% penicillin-strep-
tomycin (all from Gibco) and 100 ng/mL M-CSF (R&D Systems, Min-
neapolis, USA). After 3 days, adherent cells were seeded into 96-
well plates (1 9 106 cells/mL) and incubated with 30 ng/mL M-CSF
and 50 ng/mL RANKL (R&D Systems) with or without TLR agonists
or antagonists. Osteoclasts were identified by TRAP-staining (ie,
TRAP-positive cells with ≥3 nuclei), and mean numbers of osteo-
clasts were calculated out of three wells.
2.9 | Isolation of cells for FACS analysis and cell
culture
Splenocytes from rat or mouse spleens were isolated by passing
them through a nylon mesh and cultured in DMEM (Gibco) supple-
mented with 10% FBS (Sigma-Aldrich) and penicillin/streptomycin
(Gibco). Cells were seeded into 48-well plates and cultured in the
presence of the TLR9 agonist. The TLR9 antagonist, the TLR7 antag-
onist or the control ODN were added in increasing concentrations.
Splenocytes grown in medium alone served as negative control, cells
grown in the presence of the agonist only served as positive control.
Activation of cells was determined by measuring Interleukin (IL)-6 in
supernatants after 48 hours.
For analysis of TLR antagonist uptake, cells were seeded into 24-
well plates and incubated overnight (o/n) with 1000 nmol/L of fluo-
rescein-labelled TLR9 antagonist or control ODN. After o/n incuba-
tion the medium was removed, and the cells were incubated for up
to 72 hours without the antagonists. Uptake of oligodeoxynu-
cleotides was analyzed by flow cytometry.
2.10 | Real-time quantitative polymerase chain
reaction (RT-qPCR)
Total RNA from cells was isolated using the RNeasy mini kit (Qiagen,
Hilden, Germany). RNA was reverse transcribed into cDNA using the
Omniscript RT kit (Qiagen). RT-qPCR was performed using LightCy-
cler technology (Roche, Germany) and the Fast Start SYBR Green I
kit. The expression of the target molecule was normalized to
GAPDH. The primer sets used (all from Sigma-Aldrich) are listed in
Table S1.
2.11 | RT-qPCR from tissue extracts
Rat organs (dLN and spleens) were mechanically homogenized in
TRIfast (Peqlab), followed by isolation of total RNA according to the
manufacturer’s instructions. mRNA was reverse transcribed into
cDNA using the Omniscript RT kit (Qiagen).
2.12 | Detection of cytokines
Serum samples were obtained from anaesthetized mice and rats by
puncture of the heart. The acute phase marker a-1-acid-glycoprotein
(AGP) and rat IL-6 were measured by ELISA obtained from Life Diag-
nostics (West Chester, PA, USA) and BD Pharmingen, respectively.
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ELISAs for mouse IL-6, TNF-a and IL-10 were from Thermo Fisher
Scientific.
2.13 | Detection of rheumatoid factor
Rheumatoid factor (RF) levels in rat sera were quantified by ELISA
as published24 with minor modifications. ELISA plates (NUNC, Ros-
kilde, Denmark) were coated o/n at 4°C with 10 g/L rabbit IgG
(Sigma). Isotype-specific mouse anti-rat IgM (Pharmingen, San Diego,
CA, USA) or goat anti-rat IgG antibody (Vector, Burlingame, CA,
USA) conjugated to biotin was used for detection, followed by incu-
bation with StreptAvidin-conjugated HRP (R&D Systems). The rela-
tive concentrations of RF were determined using high-titre reference
sera obtained from rats with PIA.
2.14 | Statistical analysis
GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA) was
used for graphs and to calculate mean, standard error of the mean
(SEM), and statistical significance. Arthritis and grip strength scores
are graphically presented as mean  SEM. The area under the curve
(AUC) was used to describe the time course of arthritis and grip
strength scores. Statistics were calculated using a two-tailed non-
parametric Mann-Whitney U test. For statistical analysis of in vitro
experiments where cells of the same specimen were treated with
different compounds (ie, splenocytes and osteoclast assay), the
paired two-tailed t test was used. P-values < .05 were considered to
be statistically significant.
3 | RESULTS
3.1 | Antagonizing TLR9 reduces the severity of
pristane-induced arthritis
To investigate the role of TLR9 in autoimmune arthritis, we used an
antagonist that specifically blocks this TLR. To determine its efficacy,
the inhibitor was first tested on rat and mouse splenocytes. The
antagonist blocked TLR9-induced secretion of IL-6 dose dependently
(Figure S1A-C). To demonstrate uptake and internalization of the
antagonist, splenocytes were incubated with the fluorescein-labelled
TLR9 antagonist. The data showed that the antagonist was readily
taken up by 50%-60% of the cells and that the signal was stable for
at least 72 hours (Figure S1D). Furthermore and in line with this
observation, the TLR9 inhibitor significantly reduced secretion of IL-
6, TNF-a and IL-10 by mouse splenocytes (Figure S1E-G).
To investigate the influence of TLR9 on the development of PIA,
we injected the TLR9 inhibitor into DA.1F rats 2 days before induc-
ing arthritis. The rats were then treated twice a week with the antag-
onist, using a non-specific ODN and saline as controls (Figure 1A).
Development of PIA was assessed until the rats were sacrificed on
day 25 post-pristane injection. Rats treated with the TLR9 antagonist
developed milder clinical signs of arthritis and showed significantly
reduced paw swelling on day 25 compared with the control groups
(Figure 1B). Furthermore, loss of body weight was delayed and much
less pronounced in the group of the TLR9 antagonized rats in com-
parison with the control groups, resulting in a significantly higher end
point body weight in the treatment group (Figure 1C).
F IGURE 1 Treatment with the TLR9
antagonist IRS 869 reduces severity of
PIA. A, DA.1F rats were prophylactically
treated with the TLR9 antagonist, the
control ODN or vehicle (phosphate-
buffered saline, PBS) according to the
treatment scheme. B, Paw swelling was
assessed throughout the experiment
starting at day 10, and end-point paw
swelling was calculated for all groups at
day 25. C, Weight changes were measured
and calculated relative to the starting
weight (day 0); end-point weight change
was calculated for all groups at day 25
after disease induction. Graphs show
mean  SEM with *P < .05
(n = 6 animals/group)
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Clinical observations were confirmed by histomorphometric
quantification of paraffin-embedded sections from tarsal joints (Fig-
ure 2). Analysis of invading inflammatory cells into the joint revealed
a significant decrease in the inflammation area in TLR9 antagonized
rats compared to the control group (Figure 2A,E). In line with this,
the number of bone resorbing osteoclasts was diminished in the
TLR9 antagonist group (Figure 2B,E). In addition, the osteophyte
area was reduced in TLR9 antagonized rats as compared to the con-
trol groups (Figure 2C). Analysis of toluidine blue-stained cartilage
sections revealed a significant reduction in cartilage degradation in
joints of TLR9 antagonized animals (Figure 2D,E).
Reduction in arthritis was accompanied by reduced levels of IL-6
(Figure 3A) and the inflammatory marker alpha-1-acid glycoprotein
in sera of animals treated with the TLR9 antagonist (Figure 3B). The
occurrence of IgM-RF in PIA has previously been shown to correlate
with arthritis development.24 In line with these observations, levels
of IgM-RF, but not IgG-RF were significantly reduced in animals that
had received the TLR9 antagonist (Figure 3C,D).
3.2 | Therapeutically administered TLR9 antagonist
has no effect on the progression of PIA
Next we investigated whether the TLR9 inhibitor could affect arthri-
tis when administered therapeutically after disease induction. At the
onset of arthritis (day 14), the rats were treated twice a week with
the antagonist or vehicle until they were sacrificed on day 60 (Fig-
ure 4A). However, in contrast to prophylactic application, therapeuti-
cally administered TLR9 inhibitor did not influence the clinical
severity of arthritis (Figure 4B). In accordance with the clinical obser-
vation, inflammation, bone erosion and number of osteoclasts in the
tarsal joints were not influenced (Figure 4C).
3.3 | Expression of nucleic acid sensing TLRs in
lymphoid organs
Pristane is known to quickly accumulate in draining LNs (dLN) fol-
lowing injection,25 leading to an increased number of apoptotic cells
in the dLNs within 1-3 days.26 To further analyse the involvement
of TLR9 in the development of PIA, we isolated mRNA from spleen
and the inguinal (ie, draining) LNs. In addition to TLR9, expression of
TLR3 (dsRNA binding) and TLR7 (ssRNA binding) was assessed by
RT-qPCR. There were no differences of TLR3, 7 and 9 levels in dLNs
of rats treated with the TLR9 antagonist, control ODN or vehicle.
However, TLR9 expression was significantly decreased in all three
groups in comparison with the na€ıve control animals (Figure S2A-C).
In contrast to LNs, no differences in TLR expression could be
detected between spleens of arthritic and na€ıve rats (Figure S2D-F).
3.4 | Lack of a functional TLR9 does not affect K/
BxN serum-transfer arthritis
To further dissect the involvement of TLR9 in T cell-dependent ver-
sus T cell-independent phases of inflammatory arthritis, we
investigated disease development and progression in the K/BxN
serum-transfer model which is independent of T cells and character-
ized by a fast developing monophasic destructive arthritis in all tarsal
joints.27 C57BL/6 mice lacking a functional TLR9 (TLR9/) and their
littermate wild-type controls (TLR9+/+) were injected with K/BxN
serum to induce arthritis. TLR9 deficiency did not result in any alter-
ations in paw swelling or grip strength (Figure 5A). In accordance
with the clinical observation, the inflamed area, bone erosions, num-
ber of osteoclasts and cartilage destruction of the tarsal joints were
not influenced by the lack of TLR9 (Figure 5B). Thus, TLR9 did not
seem to have an influence on incidence and severity of serum-trans-
fer arthritis.
3.5 | TLR9 is involved in the T cell-dependent
phase of chronic SCW arthritis
To confirm the differential roles of TLR9 in T cell-dependent and T
cell-independent arthritic processes, we next investigated the
involvement of TLR9 in the course of repeated SCW arthritis, which
is characterized by a T cell-independent initial phase after the first
intra-articular SCW injection, followed by a T cell-dependent chronic
phase after the fourth SCW reactivation.11 We induced SCW arthri-
tis in TLR9/ and control wild-type mice, and quantified joint
inflammation. Joint swelling was not affected by TLR9 deficiency in
the acute phase of SCW arthritis, that is days 1 and 2 after the first
SCW injection (Figure 5C). Furthermore, the intermediate reactiva-
tion phase of arthritis post each intra-articular injection (days 8, 15
and 22) was similar between wild-type and TLR9/ mice. However,
the T cell-dependent chronic phase of SCW arthritis was significantly
suppressed in TLR9/ mice as demonstrated by reduced joint swel-
ling on days 23 and 28 (Figure 5C).
3.6 | TLR9 is differentially expressed in the course
of in vitro osteoclastogenesis
As the number of osteoclasts was substantially reduced in TLR9
antagonized rats, we became interested to analyze the impact of
TLR9 on in vitro osteoclast formation using bone marrow cells from
wild-type mice, which were cultivated in the presence or absence of
TLR9 and TLR7 antagonists or agonists, or a control ODN.
When the cells were exposed to TLR9 and TLR7 antagonists or
agonists, the formation of osteoclasts was reduced by approximately
40% by the TLR9 but not the TLR7 antagonist or the control ODN
(Figure 6A). Furthermore, in accordance with previously published
observations,28,29 both agonists completely blocked osteoclast for-
mation (Figure 6A). As the TLR9 agonist CpG has been shown to
exert different effects during in vitro osteoclastogenesis depending
on the time-point of the exposure to CpG, leading either to
enhanced or reduced osteoclast formation,29 we sought to explore
whether agonists and antagonists of TLR9 and TLR7 would still exert
a suppressive effect when cells had been pre-incubated with RANKL.
Indeed, when cells were stimulated with RANKL 3 days prior to
addition of the agonists or antagonists, the inhibitory effect
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observed for the TLR9 agonist as well as the TLR9 antagonist was
completely abolished as was the inhibitory effect of the TLR7 ago-
nist (Figure 6B).
In addition, we analyzed the expression of TLR9 and TLR7 by
RT-qPCR at different time points during in vitro osteoclastogenesis.
In osteoclast precursor cells, TLR9 expression was high on day 3 but
decreased to almost background levels after 5 days (Figure 6C).
TLR9 expression was not influenced by antagonists but on day 5
appeared to be slightly, although not significantly, increased by the
agonists, particularly by the TLR7 agonist (R-848). Expression of
TLR7 did not change between day 3 and day 5, but increased by
~2-fold upon culture with the TLR7 or the TLR9 agonist, but this
increase did not reach statistical significance (Figure 6D). Altogether,
these data suggest a dynamic regulation of TLR9 expression and a
phase-dependent role for this receptor during osteoclastogenesis.
4 | DISCUSSION
It is now widely accepted that RA is initiated by autoreactive T cells
leading to the production of pathogenic autoantibodies such as RF
or antibodies to citrullinated proteins (ACPA). However, the trigger-
ing events are still largely unknown and the autoantigens activating
arthritogenic T cells have not yet been identified. Nevertheless,
based on data obtained in patients with RA and animal models, it is
conceivable that TLRs and their endogenous ligands may play a piv-
otal role in the pathogenesis of RA. Apart from overexpression of
various TLRs in the synovium of RA patients,7,8 this has been partic-
ularly demonstrated for TLR7 in CIA,14 for both TLR2 and TLR4 in
SCW-induced arthritis9,10,30,31 and also for TLR3 in PIA.12 In previ-
ous investigations, we showed that PIA can be transferred into na€ıve
recipient rats by CD4+ T cells after in vitro re-stimulation with autol-
ogous APCs.19 Activation by nucleic acids or nucleic acid-containing
proteins (eg, hnRNP-A2/B1) was required for the APCs to regain
their stimulatory capacity, suggesting a crucial involvement of nucleic
acid-binding TLRs and their endogenous ligands in initiation of PIA.19
In accordance with these findings, we could now demonstrate that
blocking TLR9 activation led to a significant amelioration of arthritis
when the TLR9 antagonist was applied before disease induction.
Reduction in clinical severity was supported by histological examina-
tion and also by serological findings, revealing decreased levels of
the pro-inflammatory cytokine IL-6, the acute phase protein AGP
and the autoantibody IgM-RF in sera of animals treated with the
TLR9 antagonist. Reduced serum levels of IL-6, AGP and IgM-RF
may explain the early treatment effect as this could affect the T cell
activation in the first priming phase. It has been clearly shown that
pristane activates APCs priming autoreactive T cells, which induces a
chronic arthritis development.32 Thus, we assume that the major
effect of TLR9 inhibition is suppression of cytokine production and
reduced activation of APCs, leading to reduction in inflammation and
partial suppression of arthritogenic T cell responses. This is also sup-
ported by in vitro data showing substantially reduced secretion of
IL-6, TNF-a and IL-10 by splenocytes treated with the TLR9 antago-
nist. However, when the antagonist was administered therapeutically
after the onset of arthritis, no protective effects were observed,
F IGURE 3 Serum levels of IL-6, AGP and RF are reduced in rats
treated with the TLR9 antagonist. The TLR9 antagonist or vehicle
(phosphate-buffered saline, PBS) was prophylactically administered
to DA.1F rats as described. Serum samples were obtained from
anaesthetized rats by puncture of the heart on the day of
termination of the experiment. Levels of A, IL-6, B, alpha-1-acid
glycoprotein (AGP), C, RF-IgM and D, RF-IgG were determined by
ELISA. Graphs show mean  SEM with *P < .05 and ***P < .005
(n = 6 for A; n = 8-9 for B, C and D with data pooled from two
individual experiments)
F IGURE 2 Antagonizing TLR9 leads to reduced inflammation, cartilage degradation and osteoclast numbers in arthritic paws of rats with
PIA. Formalin-fixed paws were stained with H&E, toluidine blue and for TRAP. A, Inflammation, B, number of osteoclasts, C, osteophyte area
and D, cartilage loss was analyzed. Quantification was performed as described. Animals treated with the TLR9 antagonist show a reduction in
all analyzed parameters compared to animals treated with vehicle or control ODN. E, A representative picture is shown for each treatment
group and a na€ıve animal, where white arrows indicate osteoclasts and black arrows are indicative of osteophyte areas. Graphs represent
mean  SEM with *P < .05 and **P < .01 (n = 5-6 animals/group)
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F IGURE 4 Therapeutic treatment with
the TLR9 antagonist does not lead to
improvement of PIA. A, Animals were
therapeutically treated with the TLR9
antagonist, starting at disease onset (day
14). B, Paw swelling and weight changes
were measured throughout the course of
PIA. In addition, formalin-fixed paws were
analyzed and C, inflammation, erosion and
number of osteoclasts was determined.
Results are shown as mean  SEM with
n = 5-8 animals/group
F IGURE 5 Lack of TLR9 leads to a reduced T cell-dependent phase of chronic SCW-arthritis. A and B, K/BxN serum-transfer arthritis was
induced in TLR9/ and control wild-type mice. A, Clinical observation of wild-type (WT, TLR9+/+; n = 5) or TLR9 knock-out (KO, TLR9/;
n = 6) C57BL/6 mice with K/BxN serum-transfer arthritis and B, histological quantification of the tarsal joints of these mice revealed no
differences in inflammation, bone erosion, number of osteoclasts (ie, TRAP-positive cells) or cartilage loss in TLR9/ animals as compared to
wild-type mice. C, SCW arthritis was induced in TLR9/ (n = 6) and control wild-type (n = 6) mice by repeated intra-articular injections of
25 lg SCW into the right knee joint at days 0, 7, 14 and 21, and injection of saline as internal control into the left joint. Joint swelling was
determined by measuring 99mTc uptake by the right (inflamed) joint compared to the left (control) joint at several time points including the
acute (d1 and d2), reactivation (d8, d15 and d22) and the chronic (d23 and d28) phase of arthritis. Right/Left ratio of the radioactive 99mTc
signal is depicted on the Y-axis. Results are presented as mean  SEM with *P < .05 by Mann-Whitney U test versus WT mice
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indicating that PIA becomes independent of TLR9 signaling and T
cells once the disease process has been set in motion.
In line with these observations, SCW-induced arthritis in TLR9/
mice was reduced only in the T cell-dependent phase. In contrast to
PIA, the acute phase of SCW-induced arthritis is TLR2 dependent but
shifts towards a TLR4 dependency in the chronic phase, in which
TLR2 is no longer relevant. This phase is driven by T cells and com-
pletely abrogated in RAG2-deficient mice.10,11,30 In fact, chronic SCW
arthritis is also accompanied by bone destruction and enhanced
expression of RANK, RANKL and cathepsin K protein in cortical bone,
features that are also characteristic of RA. We have previously
observed that in the chronic SCW-induced arthritis model, the expres-
sion of TLR9 mRNA is up-regulated after each SCW injection and the
kinetics of TLR9 expression follows the arthritis reactivation pattern,
suggesting a potential relevance for TLR9 also in this model.33 The
data obtained in TLR9/ mice now clearly demonstrate that TLR9 is
indeed involved in this T cell-dependent phase of chronic SCW-arthri-
tis, highlighting the relevance of TLR9 in T cell-mediated arthritic pro-
cesses, and thus suggesting a potential role for endogenous TLR9
ligands also in SCW-induced arthritis.
In contrast to SCW-arthritis, TLR9 deficiency had no influence
on K/BxN serum-transfer arthritis. This model does not involve T
cells but rather reflects the effector phase of autoimmune arthritis27
and allows for studying the impact of TLR9 on innate immune
cells.34-36 This observation is therefore in full agreement with the
ineffectiveness of TLR9 inhibitory treatment when started after the
onset of PIA.
The most remarkable histological finding of prophylactic TLR9
inhibition in PIA was the almost complete absence of osteoclasts
and bone erosion. It is known that TLR9 stimulation influences the
outcome of osteoclastogenesis in a time-dependent manner, leading
to a profound reduction in osteoclastogenesis.29 To further investi-
gate this process, we performed osteoclast assays with bone mar-
row cells that had or had not been incubated with RANKL before
adding TLR antagonists or agonists. Indeed, partial inhibition of
osteoclastogenesis was achieved with the TLR9 antagonist, whereas
the TLR7 antagonist was ineffective. However, this effect was only
observed in unprimed, that is RANKL naive cells. It is conceivable
that blocking of MAPK and NF-jB signaling by the TLR9 antagonist
led to partial suppression of osteoclast formation, because both
pathways are involved in RANKL-induced osteoclast differentiation.
Of note, the previously described suppression of osteoclastogenesis
by TLR9 activation was shown to be caused by dephosphorylation
of ERK.37
Analysis of TLR expression during RANKL-induced osteoclasto-
genesis revealed different expression patterns. While expression of
TLR7 did not change much, expression of TLR9 was high at the
beginning of osteoclastogenesis but very low in mature osteoclasts,
F IGURE 6 Involvement of TLR9 and TLR7 in RANKL-induced osteoclastogenesis. Bone marrow-derived murine cells from wild-type mice
were expanded with M-CSF and subsequently incubated with M-CSF and RANKL (day 0) to induce differentiation into osteoclasts. Antagonists
of TLR9, TLR7, a control sequence (control ODN), or agonists of TLR9 (CpG) and TLR7 (R-848) were added A, either together with M-CSF and
RANKL or B, 3 days after treatment with M-CSF and RANKL. Osteoclasts (ie, multinucleated TRAP-positive cells) were identified by TRAP
staining. C and D, To analyze expression of TLR9 and TLR7 during osteoclastogenesis, cells were grown in the presence of TLR antagonists
(250 nmol/L) or agonists (50 nmol/L) or a control ODN (250 nmol/L). Cells grown in the presence of M-CSF only served as negative control.
Total RNA was isolated at different time points (ie, day 0, day 3 and day 5) during osteoclast formation in the presence of RANKL. TLR
expression was analyzed by RT-qPCR and calculated relative to expression on day 0. Bars are represented as mean  SEM of three
independent experiments with *P < .05 and **P < .01 (compared to control)
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indicating a strong down-regulation of TLR9 by RANKL while nei-
ther the TLR antagonist nor the agonist had significant influence
on the expression of TLR9. This suggests a modulatory role of
TLR9 during osteoclastogenesis and a temporal regulation of TLR9
expression during this process which may explain why TLR9 manip-
ulation (stimulation or inhibition) is ineffective in mature osteo-
clasts. From all these findings, we assume that TLR9 activation by
endogenous ligands plays an important (though not essential) role
during initiation of osteoclastogenesis while activation by exoge-
nous ligands (eg, during infection) seems to activate a suppressive
mechanism to avoid bone degradation in the course of a massive
inflammatory response. However, it must be borne in mind that all
these data were obtained in cell culture systems which only par-
tially reflect the much more complex in vivo situation and that
TLR9 inhibition did not show any significant effects on bone ero-
sion or osteoclastogenesis (as estimated from the number of TRAP-
positive cells) in serum-transfer arthritis or in established PIA.
Although the data obtained in vitro indicate involvement of TLR9
in osteoclastogenesis, its role in vivo is less obvious and requires
further investigations.
How can all these findings be reconciled with human RA? In con-
trast to systemic lupus erythematosus, antinuclear antibodies (mostly
directed to nucleic acid binding proteins) are infrequently observed
in RA and antibodies to dsDNA are virtually absent. The hallmark
antibodies of RA are antibodies to citrullinated proteins, but the
majority of the targets identified so far (eg, fibrinogen, vimentin or
alpha-enolase) are not associated with nucleic acids. Notable excep-
tions are histones which are citrullinated in vivo, especially during
apoptosis and NETosis, and hnRNP-A2/B1.38 Importantly, autoanti-
bodies and autoreactive T cells recognizing hnRNP-A2/B1 and
related proteins have been found in PIA and human RA.39-42 Given
that most ACPA-positive RA patients are reactive with citrullinated
histone peptides and/or hnRNP-A2/B1, autoimmunity to citrullinated
isoforms of nucleic acid binding proteins appears to be a common
phenomenon in RA.
Thus, we propose a pathogenetic model of erosive autoimmune
arthritis in which endogenous nucleic acids that are released from
dying cells because of an environmental adjuvant trigger (pristane,
cigarette smoke, infection, etc.) play a crucial role in the initiation of
arthritogenic autoimmune responses (directed to nucleic acid binding
proteins) on a predisposing genetic background, particularly MHC
class II, because of their ability to activate endosomal TLRs.
Taken together, our data suggest a strong impact of TLR9 on the
initiation of T cell-dependent arthritis, whereas its role in disease-
progression remains elusive as neither therapeutic application of a
TLR9 antagonist nor lack of a functional TLR9 ameliorated PIA or
serum-transfer arthritis, respectively. Concerning a potential applica-
tion of our findings for the treatment of RA, therapeutic application
of TLR9 antagonists might be considered in the very early pre-clini-
cal phases in persons at high risk for developing RA to prevent (fur-
ther) generation of harmful autoimmune reactions leading to the
inflammatory and deleterious processes in the joint characteristic
of RA.
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